Regeneron Pharmaceuticals, a U.S. biotech, is running a Phase 2 trial of REGN13335, an Anti-PDGF-B monoclonal antibody, in adults with pulmonary arterial hypertension who are already on standard treatment. It’s a randomized, placebo-controlled, quadruple-blind study (patients, doctors, investigators, and assessors are all kept in the dark during the main phase) to gauge what extra benefit REGN13335 adds on top of existing therapy. After the blinded period, an open-label extension will let participants continue on the drug.
The trial was first submitted January 2, 2026, with its last update logged May 26, 2026. No completion dates are posted yet.
Read more at this link on The Globe and Mail